Your session is about to expire
Reclast vs Prolia
Introduction
For patients with osteoporosis or other bone-related disorders, certain drugs that alter the process of bone remodeling, a cycle of resorption and formation in the skeletal system, can help in reducing bone loss and preventing fractures. Reclast and Prolia are two such drugs prescribed for these conditions. Reclast (zoledronic acid) is a bisphosphonate drug that works by inhibiting the action of osteoclasts, cells responsible for bone breakdown, thus slowing overall bone loss. It's usually given once a year as an intravenous infusion to treat osteoporosis. On the other hand, Prolia (denosumab) is classified as a monoclonal antibody; it binds to RANK ligand to inhibit its actions, thereby reducing bones' resorption rate by osteoclasts. Unlike Reclast which is administered annually, Prolia requires injections every six months.
Reclast vs Prolia Side By Side
| Attribute | Reclast | Prolia |
|---|---|---|
| Brand Name | Reclast | Prolia |
| Contraindications | Cannot be taken if you are taking, or have been taking bisphosphonates for a long period of time without breaks. Not suitable for patients with severe kidney problems or low calcium levels. | Not suitable for patients with low calcium levels, severe infections, or those allergic to denosumab. Should not be used concurrently with bisphosphonates without medical supervision. |
| Cost | $1,200 - $2,400 for a single dose infusion once a year | $1,100 for one syringe (60mg/ml) needed twice yearly |
| Generic Name | Zoledronic Acid | Denosumab |
| Most Serious Side Effect | Severe kidney problems, osteonecrosis of the jaw, atypical femur fractures | Serious infections, hypocalcemia, osteonecrosis of the jaw, unusual thigh bone fractures |
| Severe Drug Interactions | Interactions with other bisphosphonates requiring time to clear from the system to prevent dangerous interactions | May interact with drugs affecting the immune system and those altering calcium levels |
| Typical Dose | 5 mg dose administered intravenously over at least 15 minutes once a year | 60mg given as a subcutaneous injection every six months |
What is Reclast?
Zoledronic acid (the generic name for Reclast) is a bisphosphonate class drug, which marked a significant step in the treatment of osteoporosis and Paget's disease. It was first approved by the FDA in 2007. Reclast works by slowing down bone loss, effectively maintaining bone strength for longer than usual. It is prescribed for the prevention and treatment of different forms of osteoporosis, especially postmenopausal osteoporosis.
On the other hand, Denosumab (Prolia) represents a newer class of drugs known as monoclonal antibodies that work differently from bisphosphonates to treat osteoporosis. Approved by FDA in 2010, Prolia specifically targets RANK Ligand - a key factor involved in bone breakdown and resorption.
While both can significantly reduce fracture risk associated with Osteoporosis; side effects differ between these two medications due to their unique modes of action on our body's physiology.
What conditions is Reclast approved to treat?
Reclast and Prolia are both approved for the treatment of various bone health conditions:
- Postmenopausal osteoporosis to reduce the risk of fractures
- Bone loss that results from a decrease in estrogen (in women at significant risk of osteoporosis)
- Increase bone mass in men with osteoporosis
- Treatment and prevention of glucocorticoid-induced osteoporosis (for Reclast)
- Treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer, or women receiving adjuvant aromatase inhibitor therapy for breast cancer (for Prolia).
How does Reclast help with these illnesses?
Reclast helps to manage osteoporosis by reducing the amount of calcium that is lost from bones. It does this by inhibiting the activity of cells called osteoclasts, which are responsible for breaking down bone tissue. This process is part of a natural cycle in which old bone tissue is replaced with new bone tissue. However, when the activity of osteoclasts becomes too great, more old bone is broken down than can be replaced by new bone growth - leading to a net loss of bone mass and increased risk for fractures. By suppressing the action of these cells, Reclast slows down the rate at which calcium leaves your bones and thus enhances their strength and density.
Prolia also works to prevent or treat osteoporosis but it does so in a slightly different way: Prolia targets a specific protein involved in the development and function of osteoclasts (RANK Ligand). Blocking RANK Ligand decreases osteoclast formation, function and survival thereby decreasing bone resorption and increasing bone mass and strength.
Both medications have been shown effective in reducing fracture risk but they do come with some potential side effects which need careful consideration before starting treatment.
What is Prolia?
Prolia is the brand name for denosumab, a human monoclonal antibody used primarily in the treatment of osteoporosis. It works by inhibiting RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand), a protein that acts as the primary signal to promote bone removal. By blocking this, Prolia helps slow down bone loss and increase bone density.
Denosumab was first approved by the FDA in 2010. Unlike bisphosphonates such as Reclast (zoledronic acid) which are incorporated into the bone matrix and can affect bone remodeling for years after therapy has been stopped, Prolia's effects on reducing fractures are quickly reversible once treatment ends.
Its side-effect profile also differs from that of bisphosphonates: common side effects include back pain, high cholesterol levels, and bladder infections; however it does not cause gastrointestinal problems often seen with oral bisphosphonate drugs. This makes it an excellent choice especially for patients who have trouble tolerating or don't respond well to typical osteoporosis treatments like Reclast.
What conditions is Prolia approved to treat?
Prolia is well-regarded for its efficacy in treating several conditions, including:
- Postmenopausal osteoporosis with a high risk of fracture
- Bone loss due to hormonal treatments for breast or prostate cancer
- Osteoporosis in men at high risk of fracture
How does Prolia help with these illnesses?
Prolia, like Reclast, is a medication used in treating osteoporosis by affecting the bone remodeling process. It specifically targets RANK ligand, a protein essential for the formation, function and survival of cells that break down bone (osteoclasts). By binding to this protein, Prolia reduces the number and activity of these cells leading to decreased bone breakdown and increased bone mass and strength. This slows down the rate at which bones thin or weaken over time. Prolia’s unique action on RANK ligand can be particularly beneficial when patients do not respond well to bisphosphonates such as Reclast or may be combined with them under certain circumstances.
How effective are both Reclast and Prolia?
Both zoledronic acid (Reclast) and denosumab (Prolia), are FDA-approved medications for the treatment of osteoporosis, with their approvals coming just a few years apart. They act differently in the body as they target different stages of bone remodeling, hence may be prescribed under varying circumstances. Reclast is an intravenous bisphosphonate that inhibits bone resorption by suppressing osteoclast activity, while Prolia is a monoclonal antibody administered subcutaneously that prevents the development and function of osteoclasts by binding to RANKL.
A 2010 randomized controlled trial comparing these two drugs noted similar efficacy in increasing bone mineral density and reducing fracture risk. However, there were slight differences in safety profiles: infections were more common with Prolia whereas flu-like symptoms post-infusion were more common with Reclast.
In terms of wider research findings, both drugs have been shown to reduce vertebral fractures effectively but only Prolia has shown significant reduction in hip fractures among patients at high-risk. Therefore, clinicians might prefer prescribing Prolia for older patients or those who have had previous hip fractures. An important consideration when choosing between these medications is also dosing frequency; Reclast can be given once yearly while Prolia requires injections every six months.
A 2017 meta-analysis suggested that both drugs improve overall survival rates compared to placebo but did not provide evidence favoring one drug over another. Nonetheless, some studies suggest potential risks such as jaw necrosis and atypical femur fracture associated with long-term use which should be taken into account when considering treatment options.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Reclast typically prescribed?
The dosages of Reclast and Prolia differ significantly due to their unique methods of administration. For osteoporosis, a single 5 mg dose of Reclast is administered intravenously over at least 15 minutes once a year. On the other hand, Prolia is given as a subcutaneous injection of 60 mg every six months. Neither medication's dosage should be altered without consultation from your healthcare provider. The appropriateness of these medications often depends on patient-specific factors such as age, health status, and bone density.
At what dose is Prolia typically prescribed?
Prolia treatment is typically administered as a subcutaneous injection of 60mg, given once every six months. It's crucial to supplement your diet with adequate amounts of calcium and vitamin D during this treatment, as Prolia can lead to hypocalcemia. As with all medications, follow your healthcare provider's instructions carefully when on Prolia therapy. If there isn't an observable improvement in bone density or reduction in fracture incidents after the first few doses, your doctor may reassess the appropriateness of continued Prolia administration.
What are the most common side effects for Reclast?
Patients undergoing treatment with Reclast or Prolia may experience different side effects. Some of the common side effects associated with Reclast include:
- General weakness and fatigue
- Nausea, vomiting, diarrhea
- Bone pain or muscle ache
- Headache
- Dizziness
- Flu-like symptoms such as fever, chills, and body aches
On the other hand, some common side effects associated with Prolia are:
- Back pain
- Pain in your arms or legs
- Musculoskeletal pain (pain that affects the bones, muscles)
- Hypercholesterolemia (high cholesterol levels)
- Bladder infection (urinary tract infection)
It's important to note that these lists do not cover all possible side effects; more severe reactions can occur. Patients should communicate any unusual changes to their healthcare provider promptly.
Are there any potential serious side effects for Reclast?
The decision between Reclast and Prolia largely depends on individual health circumstances, but it's important to be aware of potential side effects. For Reclast:
- Hypocalcemia (low levels of calcium in your blood) that can cause muscle spasms, twitches or cramps
- Severe kidney problems including kidney failure
- Osteonecrosis of the jaw; symptoms may include jaw pain, swelling, numbness, loose teeth, gum infection or slow healing after injury or surgery involving gums
- Atypical femur fractures: unusual thigh bone fractures that are often low-trauma or stress fractures
For Prolia:
- Allergic reactions such as hives; difficulty breathing; feeling faint; swollen face, lips or tongue
- Low blood calcium levels causing severe muscle spasms/cramps/twitches/pain/numbness around mouth/lips/fingers/toes/seizures
- Serious infections leading to hospitalization due to weakened immune system
- Dermatitis/rashes/eczema which might lead to hospitalization -Severe jaw bone problems (osteonecrosis) -Unusual thighbone fractures.
Always consult with a healthcare provider before making a decision regarding these medications.
What are the most common side effects for Prolia?
Prolia can potentially cause the following side effects:
- Abdominal pain or discomfort
- Skin conditions such as eczema, rashes, or dry skin
- Lowered immune response leading to a higher susceptibility to infections
- Back and extremity pain
- Elevated cholesterol levels
- Bladder inflammation resulting in increased frequency of urination
- Insomnia and other sleep disorders -Nausea, constipation or lack of appetite
It's important to remember that every individual may respond differently to medications. Therefore it is crucial that you discuss these potential side effects with your healthcare provider before starting Prolia treatment.
Are there any potential serious side effects for Prolia?
Prolia, like any medication, can have potential side effects. Notable symptoms that may require immediate medical attention include:
- Signs of a serious allergic reaction: rash, hives or itching; swelling of the face, lips or throat; difficulty breathing.
- Hypocalcemia (low calcium levels), manifesting as spasms, twitches, or cramps in your muscles; numbness or tingling in your fingers or around your mouth.
- Serious infections such as skin problems, frequent fevers/chills/severe stomach pain.
- Severe jaw bone problems (osteonecrosis): severe pain in the jaw/teeth/gums; swelling or sores inside the mouth; loose teeth; gum infection
- Unusual thigh bone fractures: new/unusual hip/thigh/groin pain. If these occur while taking Prolia it is important to seek immediate medical assistance.
Contraindications for Reclast and Prolia?
Both Reclast and Prolia, along with most other osteoporosis medications, may cause serious side effects in some people. If you notice severe muscle, bone or joint pain; unusual thigh bone fractures; irregular heartbeat; esophageal problems or severe jaw bone problems (osteonecrosis), please seek immediate medical attention.
Neither Reclast nor Prolia can be taken if you are taking, or have been taking bisphosphonates for a long period of time without breaks. Always tell your physician which medications you are currently on; bisphosphonates will require a certain amount of time to clear from the system to prevent dangerous interactions with Reclast and Prolia.
Additionally, it's important to note that both of these drugs could lead to hypocalcemia (low calcium levels) especially in patients with kidney issues so ensuring adequate intake of calcium and vitamin D is essential while on these therapies. Regular monitoring by your healthcare provider is crucial when receiving treatment for osteoporosis using either Reclast or Prolia.
How much do Reclast and Prolia cost?
For the brand name versions of these drugs:
- The price of a single dose (5 mg) infusion of Reclast averages around $1,200 - $2,400, depending on your location and insurance coverage. This medication is administered once a year, so it works out to approximately $3.29–$6.58/day.
- The cost for one syringe (60mg/ml) of Prolia is about $1,100 which will be needed twice yearly, working out to approximately $6/day.
Thus if you are comparing brand-name Reclast and Prolia purely based on cost per day treatment basis then Prolica can be slightly more expensive than Reclast. It's important to remember that cost should not be the primary factor in determining which drug suits you best.
For generic versions: At this time there aren't any FDA approved generics available for either Zoledronic Acid (Reclast) or Denosumab (Prolia).
Popularity of Reclast and Prolia
Zoledronic acid, under the brand name Reclast, was estimated to have been prescribed to about 2.3 million people in the US in 2020. This medication accounted for approximately 10% of prescriptions for osteoporosis treatment in the US that year. Zoledronic acid is not a typical bisphosphonate drug due to its unique administration; it's given as an intravenous infusion once a year, which can be more convenient than daily or weekly oral medications.
Denosumab, available as Prolia among other brands, was prescribed to around 1.8 million individuals in the USA during that same period. In terms of overall usage within osteoporosis treatments, denosumab represents nearly 8%. The prevalence of denosumab has indeed shown an upward trend over recent years thanks largely to its twice-yearly subcutaneous injection schedule and strong efficacy data.
Conclusion
Both Reclast (zoledronic acid) and Prolia (denosumab) have proven effectiveness in the treatment and prevention of osteoporosis, backed by multiple clinical studies indicating their superiority over placebo treatments. Both drugs may be used together under careful medical supervision, although they essentially work differently. While Reclast works primarily by inhibiting bone resorption through its action on osteoclasts, Prolia acts specifically to inhibit a protein involved in bone breakdown.
In terms of prescription preferences, Reclast is often administered once yearly as an intravenous infusion while Prolia is usually given every six months as a subcutaneous injection. This difference could influence patient preference based on convenience and comfort.
While both medications are not available in generic form which can lead to higher costs for patients paying out-of-pocket, they also require close monitoring after administration due to potential side effects such as hypocalcemia or low calcium levels.
The safety profiles are comparable between the two drugs with each having specific concerns related to it; like possible severe kidney problems with Reclast and increased risk of infections with Prolia due to its action on the immune system. Therefore, patients must closely monitor their health status post-treatment initiation and seek immediate medical help if they experience any unusual symptoms.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Sheedy, K. C., Camara, M. I., & Camacho, P. M. (2015, March). Comparison Of The Efficacy, Adverse Effects, And Cost Of Zoledronic Acid And Denosumab In The Treatment Of Osteoporosis. Endocrine Practice. Elsevier BV.http://doi.org/10.4158/ep14106.or
- Dore, R. K. (2011, August). The RANKL Pathway and Denosumab. Rheumatic Disease Clinics of North America. Elsevier BV.http://doi.org/10.1016/j.rdc.2011.07.004
- Deeks, E. D. (2018, February). Denosumab: A Review in Postmenopausal Osteoporosis. Drugs & Aging. Springer Science and Business Media LLC.http://doi.org/10.1007/s40266-018-0525-7
- Dhillon, S. (2016, November). Zoledronic Acid (Reclast®, Aclasta®): A Review in Osteoporosis. Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40265-016-0662-4
- Ste-Marie, L.-G., Rakel, A., Boucher, A., & Ste-Marie, L.-G. (2011, March). Role of zoledronic acid in the prevention and treatment of osteoporosis. Clinical Interventions in Aging. Informa UK Limited.http://doi.org/10.2147/cia.s7282
- Woodis, C. B. (2008, May 27). Once-Yearly Administered Intravenous Zoledronic Acid for Postmenopausal Osteoporosis. Annals of Pharmacotherapy. SAGE Publications.http://doi.org/10.1345/aph.1k652